Retatrutide has emerged as a new pharmaceutical in the fight against obesity. This novel drug, belonging to a dual GLP-1 and GIP receptor agonist, exhibits promising results in research studies. By boosting these receptors, Retatrutide reduces hunger pangs, {promotesglucose regulation, and ultimately results in significant slimming. While further